Document Detail


Do lipid profiles of postmenopausal women under oral hormone replacement therapy remain stable or reveal a multiphasic course in time?
MedLine Citation:
PMID:  15293891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The object of this study was to compare the effects of oral conjugated estrogen (CEE) alone, CEE plus medroxyprogesterone acetate (MPA) and tibolone on lipid profiles, and investigate whether these effects change in time. Plasma lipid levels were studied for CEE (n = 49), CEE + MPA (n = 50) and tibolone (n = 51). Mean per cent changes at certain intervals were compared with their previous intervals for each therapy. Paired t-test was used for statistical analysis. CEE alone had raised high-density lipoprotein (HDL) and triglyceride levels and lowered total cholesterol and low-density lipoprotein (LDL) levels at the end of the 2-year study period. Addition of MPA to the CEE regimen weakened the effect on HDL and triglyceride, augmented the decrease in total cholesterol and did not affect LDL. The tibolone group revealed similar but more prominent effects in total cholesterol and LDL levels. HDL and triglyceride levels were significantly below baseline in the first 6 months, but HDL changes vanished and triglyceride levels remained decreased at the end of 2 years. These data did not support a correlation between lipid levels and the biphasic incidence of cardiac events that were observed in the Heart and Estrogen/progestin Replacement Study (HERS), but revealed period-dependent changes in the tibolone group.
Authors:
T Alper; M B Cetinkaya; A Kokcu; F F Yanik; E Malatyalioglu
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  18     ISSN:  0951-3590     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-08-05     Completed Date:  2004-08-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  199-205     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Ondokuz Mayis University Hospital, Samsun, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / blood,  prevention & control
Cholesterol / blood
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
Estrogen Replacement Therapy*
Estrogens, Conjugated (USP) / administration & dosage
Female
Humans
Lipids / blood*
Medroxyprogesterone Acetate / administration & dosage
Middle Aged
Norpregnenes / administration & dosage
Postmenopause
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Estrogens, Conjugated (USP); 0/Lipids; 0/Norpregnenes; 0/Triglycerides; 5630-53-5/tibolone; 57-88-5/Cholesterol; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Veralipride administered in combination with raloxifene decreases hot flushes and improves bone dens...
Next Document:  Psychological well-being and the dyadic relationship of Chinese menopausal women (and their spouses)...